N/A
N=24
Omentectomy and Metabolic Syndrome
Metabolic Syndrome · Morbid Obesity
Bottom Line
View on ClinicalTrials.gov: NCT00923260 ↗Enrolled (actual)
24
Serious AEs
4.2%
Results posted
Jun 2009
Primary outcome: Primary: Components of Metabolic Syndrome (Body Mass Index) — 44.9; 44.5 Kg/m2 — p=0.79
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Laparoscopic Roux-en-Y Gastric Bypass (Procedure); Omentectomy (Procedure)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Primary completion
- Oct 2007
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Components of Metabolic Syndrome (Body Mass Index) |
30.3; 30.7 | 0.76 |
| PRIMARY Components of Metabolic Syndrome (Body Mass Index) |
30.3; 30.7 | 0.76 |
| PRIMARY Components of Metabolic Syndrome (Body Mass Index) |
30.3; 30.7 | 0.76 |
| PRIMARY Components of Metabolic Syndrome (Body Mass Index) |
30.3; 30.7 | 0.76 |
| PRIMARY Components of Metabolic Syndrome (Body Mass Index) |
30.3; 30.7 | 0.76 |
| PRIMARY Components of Metabolic Syndrome (Systolic Blood Pressure) |
116.7; 124.3 | 0.15 |
| PRIMARY Components of Metabolic Syndrome (Systolic Blood Pressure) |
116.7; 124.3 | 0.15 |
| PRIMARY Components of Metabolic Syndrome (Systolic Blood Pressure) |
116.7; 124.3 | 0.15 |
| PRIMARY Components of Metabolic Syndrome (Systolic Blood Pressure) |
116.7; 124.3 | 0.15 |
| PRIMARY Components of Metabolic Syndrome (Systolic Blood Pressure) |
116.7; 124.3 | 0.15 |
| PRIMARY Components of Metabolic Syndrome (Diastolic Blood Pressure) |
71.7; 76.6 | 0.21 |
| PRIMARY Components of Metabolic Syndrome (Diastolic Blood Pressure) |
71.7; 76.6 | 0.21 |
| PRIMARY Components of Metabolic Syndrome (Diastolic Blood Pressure) |
71.7; 76.6 | 0.21 |
| PRIMARY Components of Metabolic Syndrome (Diastolic Blood Pressure) |
71.7; 76.6 | 0.21 |
| PRIMARY Components of Metabolic Syndrome (Diastolic Blood Pressure) |
71.7; 76.6 | 0.21 |
| PRIMARY Components of Metabolic Syndrome (Glucose) |
88.1; 89.3 | 0.75 |
| PRIMARY Components of Metabolic Syndrome (Glucose) |
88.1; 89.3 | 0.75 |
| PRIMARY Components of Metabolic Syndrome (Glucose) |
88.1; 89.3 | 0.75 |
| PRIMARY Components of Metabolic Syndrome (Glucose) |
88.1; 89.3 | 0.75 |
| PRIMARY Components of Metabolic Syndrome (Glucose) |
88.1; 89.3 | 0.75 |
| PRIMARY Components of Metabolic Syndrome (Insulin) |
7.3; 6.6 | 0.67 |
| PRIMARY Components of Metabolic Syndrome (Insulin) |
7.3; 6.6 | 0.67 |
| PRIMARY Components of Metabolic Syndrome (Insulin) |
7.3; 6.6 | 0.67 |
| PRIMARY Components of Metabolic Syndrome (Insulin) |
7.3; 6.6 | 0.67 |
| PRIMARY Components of Metabolic Syndrome (Total Cholesterol) |
157.4; 166.6 | 0.42 |
| PRIMARY Components of Metabolic Syndrome (Total Cholesterol) |
157.4; 166.6 | 0.42 |
| PRIMARY Components of Metabolic Syndrome (Total Cholesterol) |
157.4; 166.6 | 0.42 |
| PRIMARY Components of Metabolic Syndrome (Total Cholesterol) |
157.4; 166.6 | 0.42 |
| PRIMARY Components of Metabolic Syndrome (Total Cholesterol) |
157.4; 166.6 | 0.42 |
| PRIMARY Components of Metabolic Syndrome (Triglycerides) |
99.1; 118 | 0.40 |
| PRIMARY Components of Metabolic Syndrome (Triglycerides) |
99.1; 118 | 0.40 |
| PRIMARY Components of Metabolic Syndrome (Triglycerides) |
99.1; 118 | 0.40 |
| PRIMARY Components of Metabolic Syndrome (Triglycerides) |
99.1; 118 | 0.40 |
| PRIMARY Components of Metabolic Syndrome (Triglycerides) |
99.1; 118 | 0.40 |
| PRIMARY Components of Metabolic Syndrome (Low-Density Lipoproteins) |
95; 94.6 | 0.96 |
| PRIMARY Components of Metabolic Syndrome (Low-Density Lipoproteins) |
95; 94.6 | 0.96 |
| PRIMARY Components of Metabolic Syndrome (Low-Density Lipoproteins) |
95; 94.6 | 0.96 |
| PRIMARY Components of Metabolic Syndrome (Low-Density Lipoproteins) |
95; 94.6 | 0.96 |
| PRIMARY Components of Metabolic Syndrome (Low-Density Lipoproteins) |
95; 94.6 | 0.96 |
| PRIMARY Components of Metabolic Syndrome (High-Density Lipoproteins) |
42.9; 45.8 | 0.55 |
| PRIMARY Components of Metabolic Syndrome (High-Density Lipoproteins) |
42.9; 45.8 | 0.55 |
| PRIMARY Components of Metabolic Syndrome (High-Density Lipoproteins) |
42.9; 45.8 | 0.55 |
| PRIMARY Components of Metabolic Syndrome (High-Density Lipoproteins) |
42.9; 45.8 | 0.55 |
| PRIMARY Components of Metabolic Syndrome (High-Density Lipoproteins) |
42.9; 45.8 | 0.55 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Interleukine-6) |
4.3; 6.0 | 0.57 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Interleukine-6) |
4.3; 6.0 | 0.57 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Interleukine-6) |
4.3; 6.0 | 0.57 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Interleukine-6) |
4.3; 6.0 | 0.57 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (C-reactive Protein) |
8.9; 2.8 | 0.42 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (C-reactive Protein) |
8.9; 2.8 | 0.42 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (C-reactive Protein) |
8.9; 2.8 | 0.42 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (C-reactive Protein) |
8.9; 2.8 | 0.42 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Tumor Necrosis Factor-alpha) |
5.9; 4.8 | 0.71 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Tumor Necrosis Factor-alpha) |
5.9; 4.8 | 0.71 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Tumor Necrosis Factor-alpha) |
5.9; 4.8 | 0.71 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Tumor Necrosis Factor-alpha) |
5.9; 4.8 | 0.71 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Leptin) |
55; 87 | 0.59 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Leptin) |
55; 87 | 0.59 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Leptin) |
55; 87 | 0.59 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Leptin) |
55; 87 | 0.59 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Adiponectin) |
18.9; 16.4 | 0.56 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Adiponectin) |
18.9; 16.4 | 0.56 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Adiponectin) |
18.9; 16.4 | 0.56 |
| SECONDARY Acute Phase Reactants and Inflammatory Mediators (Adiponectin) |
18.9; 16.4 | 0.56 |
Summary
The aim of the present study was to evaluate the additional effect of sudden visceral fat reduction by omentectomy on Metabolic Syndrome, acute phase reactants and inflammatory mediators in patients with morbid obesity undergoing Laparoscopic Roux-en-Y Gastric Bypass.
Eligibility Criteria
Inclusion Criteria
- BMI > 35 Kg/m2
- Metabolic syndrome diagnosed
Exclusion Criteria
- Type 1 diabetes
- Uncontrolled type 2 diabetes
- Cirrhosis or active hepatitis
- Pregnancy
- Recent MI or stroke
Data sourced from ClinicalTrials.gov (NCT00923260). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.